Alligator Bioscience signs new immunotherapy research collaboration

Swedish biotech Alligator Bioscience (STO: ATORX) has entered into a research collaboration agreement has been signed with Professor Ignacio Melero of Spain’s Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Spain, to further investigate the biology of 4-1BB (CD137) as a target in cancer immunotherapy.

Alligator has two pipeline programs targeting 4-1BB, the fully owned monospecific antibody ATOR-1017, and the bispecific antibody ALG.APV-527, co-developed with Aptevo Therapeutics (Nasdaq: APVO).

Under the collaboration agreement, the team led by Prof Melero primarily will investigate the biological effects of 4-1BB activation in various pre-clinical cancer immunotherapy models. Prof Melero has acted as a scientific advisor and collaboration partner for Alligator since 2014.